DaVita (DVA) vs NewGenIvf Group (NIVF)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
DaVita is the larger company by market cap ($10.13 billion vs $80,770), about 125402.8 times the size. On valuation, NewGenIvf Group trades at a lower forward P/E (0.0x vs 9.5x for DaVita). NewGenIvf Group converts more of its revenue into profit, with a net margin of 209.0% versus 5.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DVA | NIVF |
|---|---|---|
| Share price | $161.03 | $0.0269 |
| Market cap | $10.13B | $80.77K |
| 1-day change | +3.00% | -23.14% |
| YTD return | +41.74% | — |
| 1-year return | +33.91% | — |
| 5-year return | +65.52% | — |
| P/E ratio (TTM) | 12.19 | — |
| Forward P/E | 9.52 | 0.00 |
| EPS (TTM) | $13.21 | $-34,064.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $13.64B | $4.73M |
| Revenue growth (YoY) | +6.46% | -13.01% |
| Net income (latest FY) | $746.80M | $9.88M |
| Gross margin | — | 20.22% |
| Operating margin | 14.98% | -226.95% |
| Net margin | 5.47% | 209.02% |
| 52-week high | $247.49 | $7,257.60 |
| 52-week low | $101.00 | $0.0229 |
| Distance from 52-week high | -34.93% | -100.00% |
| Analyst consensus | buy | none |
| Avg. price target upside | +38.04% | +472316.36% |
| Average volume | 738.70K | 6.57M |
| Shares outstanding | 62.90M | 2.99M |
| Employees | 78,000 | 87 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DaVita is about 125402.8 times larger than NewGenIvf Group by market value ($10.13B vs $80.77K).
- NewGenIvf Group is more profitable, keeping 209.0 cents of every revenue dollar as net income versus 5.5 cents for DaVita.
- DaVita grew revenue faster in its latest fiscal year (+6.46% vs -13.01%).
About DaVita
DVA stock →DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Health Care · Misc Health and Biotechnology Services · 78,000 employees
About NewGenIvf Group
NIVF stock →NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company provides a range of fertility treatment solutions, including in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing.
Health Care · Misc Health and Biotechnology Services · 87 employees
DVA vs NIVF FAQ
Which is bigger, DaVita or NewGenIvf Group?
DaVita (DVA) is larger, with a market capitalization of $10.13B compared with $80.77K for NewGenIvf Group (NIVF).
Are DaVita and NewGenIvf Group in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.